Prostate cancer patients undergoing androgen deprivation therapy (ADT) are susceptible to significant bone mineral density (BMD) loss, which may result in an increased risk of fracture. Bisphosphonates prevent BMD loss when initiated concurrently with ADT. In a series of studies, the bisphosphonate zoledronic acid (Zometa) was shown to increase BMD and suppress bone turnover markers in men undergoing initial ADT and to prevent bone loss as well.
Go to Previous Page
Go to Next Page